Role of VEGF and CD44v6 in differentiating benign from malignant ascites
- PMID: 14606105
- PMCID: PMC4656549
- DOI: 10.3748/wjg.v9.i11.2596
Role of VEGF and CD44v6 in differentiating benign from malignant ascites
Abstract
Aim: To detect the vascular endothelial growth factor (VEGF) and soluble splice variant 6 of CD44 (sCD44v6) levels in ascites and to explore their role in differentiating benign from malignant ascites.
Methods: Cirrhotic ascites (n=36), tuberculosis ascites (n=8) and malignant ascites (n=23) were collected and studied. Concentrations of soluble VEGF and sCD44v6 in various kinds of ascites (n=67) were measured using a sandwich enzyme-linked immunoadsorbent assay.
Results: VEGF and sCD44v6 levels in malignant ascites were 640.74+/-264.81 pg/ml and 89.22+/-38.20 ng/ml, respectively, both of which were significantly higher than those in cirrhotic ascites and tuberculous ascites (q=18.98, 11.89 and q=8.92, 5.09; P<0.01). However, the levels of VEGF and sCD44v6 in cirrhotic and tuberculous ascites had no significant difference (q=0.48, 0.75; P>0.05). Furthermore, VEGF levels in malignant ascites in patients with ovarian cancer were higher than those with gastric and colon cancer (q=5.03, 6.79; P<0.01, respectively). But differences of VEGF levels between gastric and colon cancer were not significant (q=1.90, P>0.05). Whereas, sCD44v6 levels in malignant ascites from patients with ovarian, gastric and colon cancer had no significant difference (q=0.06, 0.91, 0.35; P>0.05, respectively). In comparison with cirrhotic and tuberculous ascites, when the upper limit of its VEGF mean levels 119.44 pg/ml (70.90+/-48.54) and sCD44v6 mean levels 63.59 ng/ml (44.42+/-19.17) was taken as the minimum cutoff limit, the sensitivity and specificity of VEGF and sCD44v6 of this assay to the diagnosis of malignant ascites were 91.3%, 90.9% and 73.9%, 88.7% respectively.
Conclusion: Elevated levels of VEGF and sCD44v6 may be useful in differential diagnosis of benign and malignant ascites.
Figures



Similar articles
-
Detection of type IV collagenase activity in malignant ascites.World J Gastroenterol. 2003 Nov;9(11):2592-5. doi: 10.3748/wjg.v9.i11.2592. World J Gastroenterol. 2003. PMID: 14606104 Free PMC article.
-
Correlation of cytologic examination with ELISA assays for hyaluronan and soluble CD44v6 levels in evaluation of effusions.Diagn Cytopathol. 2007 Feb;35(2):105-10. doi: 10.1002/dc.20585. Diagn Cytopathol. 2007. PMID: 17230576
-
The clinical significance of vascular endothelial growth factor in malignant ascites.Tumour Biol. 2016 Mar;37(3):3719-25. doi: 10.1007/s13277-015-4198-0. Epub 2015 Oct 13. Tumour Biol. 2016. PMID: 26462841
-
[Differential diagnosis and pathophysiologic principles of ascites].Chirurg. 1993 Jan;64(1):1-6. Chirurg. 1993. PMID: 8382146 Review. German. No abstract available.
-
[Laboratory chemical analysis in ascites].Schweiz Med Wochenschr. 1991 Apr 13;121(15):536-47. Schweiz Med Wochenschr. 1991. PMID: 2035010 Review. German.
Cited by
-
Control values of ovarian cancer tumor markers and standardisation of a protocol for sampling peritoneal fluid and performing washing during laparoscopy.World J Surg Oncol. 2014 Sep 4;12:278. doi: 10.1186/1477-7819-12-278. World J Surg Oncol. 2014. PMID: 25185697 Free PMC article.
-
Blockade of TGF-β and PD-L1 by bintrafusp alfa promotes survival in preclinical ovarian cancer models by promoting T effector and NK cell responses.Br J Cancer. 2024 Jun;130(12):2003-2015. doi: 10.1038/s41416-024-02677-9. Epub 2024 Apr 15. Br J Cancer. 2024. PMID: 38622286 Free PMC article.
-
Simple patterned nanofiber scaffolds and its enhanced performance in immunoassay.PLoS One. 2013 Dec 10;8(12):e82888. doi: 10.1371/journal.pone.0082888. eCollection 2013. PLoS One. 2013. PMID: 24340065 Free PMC article.
-
A Novel Combination of C-Reactive Protein and Vascular Endothelial Growth Factor in Differential Diagnosis of Ascites.J Gastrointest Cancer. 2017 Mar;48(1):50-57. doi: 10.1007/s12029-016-9873-x. J Gastrointest Cancer. 2017. PMID: 27614744
-
Ascitic Fluid Analysis in the Differential Diagnosis of Ascites: Focus on Cirrhotic Ascites.J Clin Transl Hepatol. 2014 Mar;2(1):58-64. doi: 10.14218/JCTH.2013.00010. Epub 2014 Mar 15. J Clin Transl Hepatol. 2014. PMID: 26357618 Free PMC article. Review.
References
-
- Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature. 1989;339:58–61. - PubMed
-
- Masood R, Cai J, Zheng T, Smith DL, Hinton DR, Gill PS. Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood. 2001;98:1904–1913. - PubMed
-
- Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246:1306–1309. - PubMed
-
- Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983;219:983–985. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous